Biosceptre secures Technology Strategy Board Award
Award to develop new therapeutic antibodies targeting nf-P2X7 to treat cancer [...]
Biosceptre moves corporate headquarters to the UK from Australia
Move provides greater access to investors, grants, partners and expertise [...]